Oral erythromycin and the risk of sudden death.
Amory
John K
JK
Amory
David W
DW
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors*; D001628:Beverages; D032083:Citrus paradisi / Q000378:metabolism*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000009:adverse effects*; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004347:Drug Interactions; D004917:Erythromycin / Q000009:adverse effects*; D006801:Humans; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors*
D000900:Anti-Bacterial Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D004917:Erythromycin; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating